A Study of BL-M07D1 With or Without Pertuzumab Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

June 5, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
HER2-positive Breast Cancer
Interventions
DRUG

BL-M07D1

Administration by intravenous infusion for a cycle of 3 weeks.

DRUG

Pertuzumab

Administration by intravenous infusion for a cycle of 3 weeks.

Trial Locations (30)

Unknown

NOT_YET_RECRUITING

The First Affiliated Hospital of Bengbu Medical University, Bengbu

NOT_YET_RECRUITING

Anhui Provincial Cancer Hospital, Hefei

NOT_YET_RECRUITING

The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei

NOT_YET_RECRUITING

The First Affiliated Hospital of Chongqing Medical University, Chongqing

NOT_YET_RECRUITING

Fujian Medical University Union Hospital, Fuzhou

NOT_YET_RECRUITING

Guangdong Maternal and Child Health Center, Guangzhou

NOT_YET_RECRUITING

Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou

NOT_YET_RECRUITING

Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen

NOT_YET_RECRUITING

Liuzhou People's Hospital, Liuzhou

NOT_YET_RECRUITING

Guangxi Medical University Cancer Hospital, Nanning

NOT_YET_RECRUITING

Hainan General Hospital, Haikou

NOT_YET_RECRUITING

The Fourth Hospital of Hebei Medical University, Shijiazhuang

NOT_YET_RECRUITING

Xingtai People's Hospital, Xingtai

NOT_YET_RECRUITING

Harbin Medical University Cancer Hospital, Harbin

NOT_YET_RECRUITING

Anyang Cancer Hospital, Anyang

NOT_YET_RECRUITING

The First Affiliated Hospital of Henan University of science and technology, Luoyang

NOT_YET_RECRUITING

Henan Provincial People's Hospital, Zhengzhou

NOT_YET_RECRUITING

Hunan Cancer Hospital, Changsha

NOT_YET_RECRUITING

The Second Xiangya Hospital of Central South University, Changsha

NOT_YET_RECRUITING

The First Affiliated Hospital of Nanchang University, Nanchang

NOT_YET_RECRUITING

Shaanxi Provincial People's Hospital, Xi'an

NOT_YET_RECRUITING

The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an

NOT_YET_RECRUITING

Shandong Cancer Hospital, Jinan

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

NOT_YET_RECRUITING

Shanxi Bethune Hospital, Taiyuan

NOT_YET_RECRUITING

Shanxi Cancer Hospital, Taiyuan

NOT_YET_RECRUITING

Sichuan Cancer Hospital, Chengdu

NOT_YET_RECRUITING

Tianjin Cancer Hospital, Tianjin

NOT_YET_RECRUITING

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

NOT_YET_RECRUITING

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors
collaborator

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

INDUSTRY

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY

NCT06891833 - A Study of BL-M07D1 With or Without Pertuzumab Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer | Biotech Hunter | Biotech Hunter